Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | SELL | P14151 | 1/20 | 0.41 |
| ▸ | SELP | P16109 | 1/20 | 0.41 |
| ▸ | FUT4 | P22083 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL742346 | 0.99 | ALDH1A1 (0.42) | ALDH1A1KDM4EMAPTHPGDHSD17B10 | |
| Gallic Acid SCHEMBL28942553 | 0.87 | KDM4A (0.44) | ALDH1A1KDM4EMAPTHPGDHSD17B10 | |
| Gallic Acid SCHEMBL29690927 | 0.87 | KDM4A (0.44) | ALDH1A1KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL745518 | 0.85 | GRIN2D (0.43) | ALDH1A1KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL744734 | 0.84 | CA12 (0.48) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL745566 | 0.84 | GRIN2D (0.44) | ALDH1A1KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL745266 | 0.84 | GRIN2D (0.44) | ALDH1A1KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL860353 | 0.84 | GRIN2D (0.44) | ALDH1A1KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL743927 | 0.83 | CA12 (0.49) | ALDH1A1KDM4EHPGDHSD17B10LMNA | |
| SCHEMBL860748 | 0.78 | ALDH1A1 (0.41) | ALDH1A1KDM4EMAPTHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260091003-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | BPGBIO INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260034073-A1 | COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA | BPGBIO INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-2983654-B1 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGBIO INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12303471-B2 | Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 | BPGBIO, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12209285-B2 | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) | BPGBIO, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-11452699-B2 | Method of treating or preventing tumors of the central nervous system | BERG LLC (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220202741-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | BERG, KARA ANN | 2022-06-30 | — | — | US | disclosed |
| US-20220096400-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 IN COMBINATION WITH IMMUNE CHECKPOINT MODULATORS | THLIVERIS, ANDREW T. | 2022-03-31 | — | — | US | disclosed |
| US-20220096399-A1 | METHODS OF TREATMENT OF SOLID TUMORS USING COENZYME Q10 | BERG LLC (US) | 2022-03-31 | — | — | US | disclosed |
| US-20110064747-A1 | METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | BERG PHARMA LLC | 2011-03-17 | — | — | US | disclosed |
| WO-2011031503-A2 | METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | CYTOTECH LABS, LLC (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110027247-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | BERG LLC | 2011-02-03 | — | — | US | disclosed |
| US-20110020312-A1 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | BERG LLC | 2011-01-27 | — | — | US | disclosed |
| WO-2010132479-A2 | METHODS FOR THE DIAGNOSIS OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132502-A2 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132507-A2 | METHODS FOR TREATMENT OF DISEASE USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132440-A2 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009052186-A1 | METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209285-B2 | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) | SLC25A20, NDUFB10, NDUFA10 | ALDH1A1 778/4885KDM4E 2057/4885MAPT 3697/4885 |
| US-20260034073-A1 | COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA | VEGFA, NDUFA10, NDUFB10 | ALDH1A1 455/4885KDM4E 1631/4885MAPT 875/4885 |
| US-20220202741-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | NDUFB10, NDUFA10, NDUFB5 | ALDH1A1 766/4885KDM4E 554/4885MAPT 3207/4885 |
| US-20220096400-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 IN COMBINATION WITH IMMUNE CHECKPOINT MODULATORS | NDUFA10, NDUFB10, NDUFA5 | ALDH1A1 519/4885KDM4E 925/4885MAPT 3522/4885 |
| US-20260091003-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | NDUFA10, NDUFB10, NDUFA5 | ALDH1A1 586/4885KDM4E 828/4885MAPT 1226/4885 |
| US-20110020312-A1 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | PC, GLS2, PCK2 | ALDH1A1 867/4885KDM4E 2944/4885MAPT 1483/4885 |
| US-20110027247-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | SLC25A20, NDUFB10, NDUFA10 | ALDH1A1 778/4885KDM4E 2057/4885MAPT 3697/4885 |
| US-11452699-B2 | Method of treating or preventing tumors of the central nervous system | NDUFB10, NDUFA10, COQ8A | ALDH1A1 1181/4885KDM4E 3221/4885MAPT 1918/4885 |
| US-12303471-B2 | Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 | NDUFB10, NDUFA10, NDUFB5 | ALDH1A1 766/4885KDM4E 554/4885MAPT 3207/4885 |
| US-20220096399-A1 | METHODS OF TREATMENT OF SOLID TUMORS USING COENZYME Q10 | NDUFB10, NDUFA10, NDUFB5 | ALDH1A1 1013/4885KDM4E 1485/4885MAPT 4464/4885 |
| US-20110064747-A1 | METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | NDUFB10, SDHB, SDHA | ALDH1A1 702/4885KDM4E 1022/4885MAPT 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.